The STAT3 oncogene as a predictive marker of drug resistance

Benjamin Barré, Arnaud Vigneron, Neil Perkins, Igor B Roninson, Erick Gamelin, Olivier Coqueret

    Research output: Contribution to journalArticle

    94 Citations (Scopus)

    Abstract

    Constitutive activation of STAT3 (signal transducer and activator of transcription) has been reported in several primary cancers and tumor cell lines where it induces cell transformation through a combined inhibition of apoptosis and cell-cycle activation. Several studies have suggested that STAT3 prevents cell-cycle arrest and cell death through upregulation of survival proteins and downregulation of tumor suppressors. As a consequence of anti-apoptotic and proliferative lesions, we propose that this oncogenic pathway is also involved in intrinsic drug resistance and that STAT3-expressing tumors are resistant to chemotherapeutic agents. If this hypothesis is correct, the detection of the activated form of this protein should help to define subsets of tumors that fail to respond to chemotherapy. Furthermore, interfering with the STAT3 oncogenic pathway might restore the sensitivity to anticancer drugs.
    Original languageEnglish
    Pages (from-to)4-11
    Number of pages8
    JournalTrends in Molecular Medicine
    Volume13
    Issue number1
    DOIs
    Publication statusPublished - 2007

    Keywords

    • Apoptosis
    • Biological Markers
    • Cell Transformation, Neoplastic
    • Drug Resistance, Neoplasm
    • Humans
    • Neoplasms
    • STAT3 Transcription Factor
    • Signal Transduction

    Fingerprint Dive into the research topics of 'The STAT3 oncogene as a predictive marker of drug resistance'. Together they form a unique fingerprint.

  • Cite this

    Barré, B., Vigneron, A., Perkins, N., Roninson, I. B., Gamelin, E., & Coqueret, O. (2007). The STAT3 oncogene as a predictive marker of drug resistance. Trends in Molecular Medicine, 13(1), 4-11. https://doi.org/10.1016/j.molmed.2006.11.001